JP2007501632A - 栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法 - Google Patents
栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法 Download PDFInfo
- Publication number
- JP2007501632A JP2007501632A JP2006532533A JP2006532533A JP2007501632A JP 2007501632 A JP2007501632 A JP 2007501632A JP 2006532533 A JP2006532533 A JP 2006532533A JP 2006532533 A JP2006532533 A JP 2006532533A JP 2007501632 A JP2007501632 A JP 2007501632A
- Authority
- JP
- Japan
- Prior art keywords
- dietary supplement
- supplement
- dietary
- polar lipid
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 227
- 241000283086 Equidae Species 0.000 title claims abstract description 99
- 206010061459 Gastrointestinal ulcer Diseases 0.000 title claims abstract description 41
- 241001465754 Metazoa Species 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 17
- 239000004615 ingredient Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 20
- 241000283073 Equus caballus Species 0.000 claims description 86
- 210000002784 stomach Anatomy 0.000 claims description 73
- 150000002632 lipids Chemical class 0.000 claims description 66
- 235000007319 Avena orientalis Nutrition 0.000 claims description 62
- 244000075850 Avena orientalis Species 0.000 claims description 62
- 239000003921 oil Substances 0.000 claims description 55
- 235000019198 oils Nutrition 0.000 claims description 55
- 239000013589 supplement Substances 0.000 claims description 52
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 38
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 37
- 239000000835 fiber Substances 0.000 claims description 33
- 231100000678 Mycotoxin Toxicity 0.000 claims description 29
- 239000002636 mycotoxin Substances 0.000 claims description 29
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 28
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 25
- 229920002498 Beta-glucan Polymers 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 20
- 244000052769 pathogen Species 0.000 claims description 19
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 16
- 229930182816 L-glutamine Natural products 0.000 claims description 16
- 239000004473 Threonine Substances 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000002496 gastric effect Effects 0.000 claims description 13
- 229960002898 threonine Drugs 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 230000002745 absorbent Effects 0.000 claims description 11
- 239000002250 absorbent Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 210000004379 membrane Anatomy 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000006052 feed supplement Substances 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 240000005979 Hordeum vulgare Species 0.000 claims description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 2
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000006096 absorbing agent Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 206010023799 Large intestinal ulcer Diseases 0.000 abstract description 18
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 16
- 201000005917 gastric ulcer Diseases 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000025865 Ulcer Diseases 0.000 description 31
- 231100000397 ulcer Toxicity 0.000 description 31
- 230000001965 increasing effect Effects 0.000 description 29
- 235000005911 diet Nutrition 0.000 description 27
- 230000037213 diet Effects 0.000 description 25
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 23
- 238000011156 evaluation Methods 0.000 description 20
- 210000004211 gastric acid Anatomy 0.000 description 20
- 241000777300 Congiopodidae Species 0.000 description 16
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 14
- 230000029087 digestion Effects 0.000 description 13
- 230000008901 benefit Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 150000001768 cations Chemical class 0.000 description 10
- 210000003296 saliva Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 150000001450 anions Chemical class 0.000 description 7
- 229940069428 antacid Drugs 0.000 description 7
- 239000003159 antacid agent Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 210000002249 digestive system Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 235000011868 grain product Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000007897 gelcap Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000009304 pastoral farming Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000007558 Avena sp Nutrition 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- -1 Chlorine ions Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000004674 intestinal mucosal integrity Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000009925 jellying Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000004678 mucosal integrity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940106721 tagamet Drugs 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940108322 zantac Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/807—Poultry or ruminant feed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Plant Substances (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
現在、大部分のウマは、一日中飼い葉を食べることができる牧草地にいるわけでもないし、馬小屋で飼い葉を給餌されているわけでもない。その代わりに、馬小屋に入れられている馬は通常、濃縮された、少量の穀物製品の食餌が与えられており、比較的少量の干し草または飼い葉がウマにとって摂取可能であり、断続的にのみ摂取可能である。競走馬および他の競技馬に関しては、その食餌は、飼い葉の食餌とあまり類似していない。競走馬は、筋肉の発達および活動レベルを最大にするために高エネルギー食餌が与えられている;この食餌は一般に、各食餌で通常、1つまたは2つのフレーク形状の最小限の干し草と共に、穀物、糖蜜、栄養素、および餌用添加剤からなる。
2頭のうち1頭が請求されたことを除いては、すべてのウマの潰瘍を調べた(内視鏡を使用して、それを調べることによって決定した)。臨床評価を開始して8週間後に、4頭のウマの無作為選択を調べた。8週目の検査で調べられたウマのうち2頭は臨床評価の開始時に潰瘍を生じておらず、8週目の検査でも潰瘍はなかった。グレード1〜2の潰瘍を有する1頭のウマは8週目の検査で瘢痕化のみを有し、潰瘍は消失していた。これはかなりの改善を意味する。グレード3の潰瘍を有する他のウマは8週目の検査でグレード1の潰瘍を有し、またかなりの改善を示した。
さらに、臨床評価の開始後の10レースについて各馬の獲得賞金総額によって判定されるように、ウマは一貫して、臨床評価の前よりも、臨床評価の開始後により良く性能を発揮した。ウマの平均賞金額は、臨床評価開始前の10レースについてのその賞金総額と比較して63%増加した。さらに注目すべきことには、この期間中に請求されたウマ2頭は、臨床評価の開始時のそれらの評価市場価値に対して250%を超える価値で請求された。
臨床評価の開始直前およびその後約2週間ごとに、すべてのウマに完全な血液検査を行った。行われた検査は血球数(「RBC」)、ヘモグロビン(血液の酸素運搬能力の基準である「HGB」)、ヘマトクリット(血液中の赤血球容積である「HCT」)、カルシウム、重炭酸塩(血液の補外pH(extrapolated pH)である「バイカーボ(Bicarbo)」)、塩素イオンおよび総タンパク質であった。8週間の期間にわたるこれらの試験それぞれの結果を本明細書にまとめる。
本発明の栄養補助食品を使用することによってウマに付与される実質的な特典のさらに他の指標がある。その指標は、調教師、獣医師、乗り手(騎手を含む)などの訓練を受けたウマの専門家、および所有者、ならびにウマ好きの人の主観的観察である。栄養補助食品を摂取しているウマは、より活発であり、より健康であるように見え(多くの人が、そのウマが以前には持っていなかった輝きを持っていると述べた)、より満足しているように見えた(おそらく、潰瘍が無いため)。さらに、調教師および騎手の見解では、以前よりもよく反応するようになった。これらの主観的結果は、上述の客観的結果と完全に一致した。本発明の栄養補助食品の成分およびそれらの相互作用の上記の論述から、本発明の栄養補助食品によって達成される特典は、栄養補助食品の成分それぞれの単独での特典の合計よりもかなり大きいことは、当業者には容易に理解されよう。
Claims (61)
- 消化管潰瘍を治療および/または抑制するのに使用される栄養補助食品であって:
胃の内壁をライニングする腸粘膜を強化する極性脂質サプリメント;
栄養補助食品と共に摂取された食料が胃を通過するのを遅くする可溶性繊維:
消化管膜の完全性を高めるニュートリシン;を含む栄養補助食品。 - 前記極性脂質サプリメンが酸化防止剤を含有する、請求項1に記載の栄養補助食品。
- 前記極性脂質サプリメントがカラスムギの脂質を含有する、請求項1に記載の栄養補助食品。
- 前記極性脂質サプリメントが、カラスムギ油、ダイズ油、オリーブ油、パーム油、ヒマワリ油、トウモロコシ油、ナタネ油、およびアマニ油からなる群から選択される少なくとも1種類の油を含む、請求項1に記載の栄養補助食品。
- 前記極性脂質サプリメントがカラスムギ油を含む、請求項1に記載の栄養補助食品。
- 前記カラスムギ油が、抽出プロセスのすべての相からのカラスムギ油の混合物を含む、請求項5に記載の栄養補助食品。
- 前記極性脂質サプリメントがさらに、抽出プロセスの最後の相からのカラスムギ油を含み、抽出プロセスの最後の相からの前記カラスムギ油が濃く、比較的高い粘度を有する、請求項5に記載の栄養補助食品。
- 前記極性脂質サプリメントが、
抽出プロセスのすべての相からのカラスムギ油約20〜80重量%;
抽出プロセスの最後の相からのカラスムギ油約20〜80重量%;を含む、請求項7に記載の栄養補助食品。 - 前記極性脂質サプリメントが、
抽出プロセスのすべての相からのカラスムギ油約62重量%;
抽出プロセスの最後の相からのカラスムギ油約38重量%;を含む、請求項8に記載の栄養補助食品。 - 前記極性脂質サプリメントが、カラスムギからのそれらのそれぞれの収量で生成されるブレンドにおいて前記カラスムギ油および抽出プロセスの最後の相からの前記カラスムギ油を含む、請求項7に記載の栄養補助食品。
- 前記極性脂質サプリメントが、前記栄養補助食品の約29〜80重量%を構成する、請求項1に記載の栄養補助食品。
- 前記極性脂質サプリメントが、前記栄養補助食品の約40〜65重量%を構成する、請求項11に記載の栄養補助食品。
- 前記極性脂質サプリメントが、前記栄養補助食品の約52.5重量%を構成する、請求項12に記載の栄養補助食品。
- 前記可溶性繊維が、カラスムギ、オオムギ、およびダイズからなる群から選択される少なくとも1種類の成分に由来する、請求項1に記載の栄養補助食品。
- 前記可溶性繊維がカラスムギに由来する、請求項1に記載の栄養補助食品。
- 前記可溶性繊維がβ−グルカン(ベータ−グルカン)を含む、請求項1に記載の栄養補助食品。
- 前記β−グルカンがカラスムギに由来する、請求項16に記載の栄養補助食品。
- 前記可溶性繊維が、前記栄養補助食品の約10〜50重量%を構成する、請求項1に記載の栄養補助食品。
- 前記可溶性繊維が、前記栄養補助食品の約15〜40重量%を構成する、請求項18に記載の栄養補助食品。
- 前記極性脂質サプリメントが、前記栄養補助食品の約52.5重量%を構成する、請求項19に記載の栄養補助食品。
- 前記ニュートリシンが、1種または複数種の界面活性剤アミノ酸を含む、請求項1に記載の栄養補助食品。
- 前記の1種または複数種の界面活性剤アミノ酸がL−トレオニンを含む、請求項21に記載の栄養補助食品。
- 前記L−トレオニンが、前記栄養補助食品の約1〜8重量%を構成する、請求項22に記載の栄養補助食品。
- 前記L−トレオニンが、前記栄養補助食品の約2.5重量%を構成する、請求項23に記載の栄養補助食品。
- 前記の1種または複数種の界面活性剤アミノ酸がL−グルタミンを含む、請求項21に記載の栄養補助食品。
- 前記L−グルタミンが、前記栄養補助食品の約1〜5重量%を構成する、請求項25に記載の栄養補助食品。
- 前記L−グルタミンが、前記栄養補助食品の約2重量%を構成する、請求項26に記載の栄養補助食品。
- 消化管におけるマイコトキシンおよび/または病原体を吸収かつ排除するニュートリシンをさらに含む、請求項1に記載の栄養補助食品。
- 消化管におけるマイコトキシンおよび/または病原体を吸収かつ排除する前記ニュートリシンが、病原性細菌吸収剤を含む、請求項28に記載の栄養補助食品。
- 前記病原性細菌吸収剤が、Alltech社により商標BIOMOSとして市販されている物質を含む、請求項29に記載の栄養補助食品。
- 前記病原性細菌吸収剤が、前記栄養補助食品の約2〜5重量%を構成する、請求項29に記載の栄養補助食品。
- 前記病原性細菌吸収剤が、前記栄養補助食品の約2.5重量%を構成する、請求項31に記載の栄養補助食品。
- 消化管におけるマイコトキシンおよび/または病原体を吸収かつ排除する前記ニュートリシンが、マイコトキシン吸収剤を含む、請求項28に記載の栄養補助食品。
- 前記マイコトキシン吸収剤が、Alltech社により登録商標MYCOSORBとして市販されている物質を含む、請求項33に記載の栄養補助食品。
- 前記マイコトキシン吸収剤が、前記栄養補助食品の約2〜5重量%を構成する、請求項33に記載の栄養補助食品。
- 前記マイコトキシン吸収剤が、前記栄養補助食品の約2.5重量%を構成する、請求項35に記載の栄養補助食品。
- pHバランサーをさらに含む、請求項1に記載の栄養補助食品。
- 前記pHバランサーが重炭酸ナトリウムを含む、請求項37に記載の栄養補助食品。
- 前記pHバランサーが、前記栄養補助食品に対して、前記栄養補助食品を中性のpHにするのに十分なパーセンテージを占める、請求項37に記載の栄養補助食品。
- 前記pHバランサーが、前記栄養補助食品に対して、前記栄養補助食品をpH約7にするのに十分なパーセンテージを占める、請求項39に記載の栄養補助食品。
- 前記pHバランサーが、前記栄養補助食品の約2重量%を構成する、請求項39に記載の栄養補助食品。
- 前記栄養補助食品の他の成分と共に運ばれる薬物をさらに含み、前記薬物の吸収値または治療値の少なくとも1つが、前記栄養補助食品と共に摂取することによって最大化される、請求項1に記載の栄養補助食品
- ウマまたは他の動物における消化管潰瘍を治療および/または抑制するのに使用される飼料サプリメントであって:
カラスムギ油ベースの極性脂質サプリメント;
β−グルカン(β−グルカン)可溶性繊維;
消化管膜の完全性を高める界面活性剤アミノ酸ベースのニュートリシン;
消化管におけるマイコトキシンおよび/または病原体を吸収するニュートリシン;および
飼料サプリメントのpHをおおよそ中性のpHレベルに維持するために、飼料サプリメントにおける他の成分に添加されるpHバランサー;を含む飼料サプリメント。 - 消化管潰瘍を治療および/または抑制するのに使用される栄養補助食品であって:
腸粘膜が胃の内壁を保護するその能力を維持するのを助ける、胃の内壁をライニングする腸粘膜を強化する第1成分;
栄養補助食品と共に摂取された食料が胃を通過するのを遅くする第2成分;
胃の内壁をライニングする腸粘膜の完全性を高める第3成分;を含む栄養補助食品。 - 前記第1成分が極性脂質サプリメントを含む、請求項44に記載の栄養補助食品。
- 前記極性脂質サプリメントがカラスムギ油を含む、請求項45に記載の栄養補助食品。
- 前記第2成分が可溶性繊維を含む、請求項44に記載の栄養補助食品。
- 前記可溶性繊維がβ−グルカン(ベータ−グルカン)を含む、請求項47に記載の栄養補助食品。
- 前記β−グルカンがカラスムギに由来する、請求項48に記載の栄養補助食品。
- 前記第3成分が、消化管膜の完全性を高めるニュートリシンを含む、請求項44に記載の栄養補助食品。
- 前記ニュートリシンが、1種または複数種の界面活性剤アミノ酸を含む、請求項50に記載の栄養補助食品。
- 前記界面活性剤アミノ酸が、L−トレオニン;およびL−グルタミン;を含む、請求項51に記載の栄養補助食品。
- 消化管におけるマイコトキシンおよび/または病原体を吸収かつ排除する第4成分をさらに含む、請求項44に記載の栄養補助食品。
- 前記第4成分が病原性細菌吸収剤を含む、請求項53に記載の栄養補助食品。
- 前記第4成分がマイコトキシン吸収剤を含む、請求項53に記載の栄養補助食品。
- 前記栄養補助食品を中性のpHにするためのpHバランサーをさらに含む、請求項44に記載の栄養補助食品。
- 極性脂質サプリメント;
可溶性繊維;および
消化管膜の完全性を高めるニュートリシン;を含む栄養補助食品。 - ウマまたは他の動物のための飼料サプリメントを製造する方法であって:
極性脂質サプリメントを提供する段階;
可溶性繊維を提供する段階;
消化管膜の完全性を高めるニュートリシンを提供する段階;および
前記極性脂質サプリメントと、前記可溶性繊維と、消化管膜の完全性を高める前記ニュートリシンを共に混合する段階;を含む方法。 - ウマまたは他の動物のための飼料サプリメントを製造する方法であって:
極性脂質サプリメントを提供する段階;
可溶性繊維を提供する段階;
消化管膜の完全性を高めるニュートリシンを提供する段階;および
消化管におけるマイコトキシンおよび/または病原体を吸収するニュートリシンを提供する段階;
前記極性脂質サプリメントと、前記可溶性繊維と、消化管膜の完全性を高める前記ニュートリシンと、マイコトキシンおよび/または病原体を吸収する前記ニュートリシンとを共に混合する段階;
前記極性脂質サプリメントと、前記可溶性繊維と、消化管膜の完全性を高める前記ニュートリシンと、マイコトキシンおよび/または病原体を吸収する前記ニュートリシンとの混合物にpHバランサーを添加して、飼料サプリメントのpHをおおよそ中性のpHレベルに維持する段階;を含む方法。 - ウマまたは他の動物における消化管潰瘍を治療および/または抑制するのに使用される栄養補助食品を給餌する方法であって、
極性脂質サプリメント;
可溶性繊維;
消化管膜の完全性を高めるニュートリシン;を含む、適切なサイズの用量の栄養補助食品を調製する段階と、
ウマまたは他の動物に前記栄養補助食品を日常的に投与する段階と、
前記調製段階および投与段階を少なくとも1日1回繰り返す段階と、を含む方法。 - ウマまたは他の動物において薬物を投与するのに使用される、栄養補助食品を利用する方法であって、
前記栄養補助食品で消化管を有効にコーティングする拡散剤として働く極性脂質サプリメント;
摂取された食品が胃を通過するのを遅くするための可溶性繊維;
消化管膜の完全性を高めるニュートリシン;
消化管におけるマイコトキシンおよび/または病原体を吸収かつ排除するニュートリシン;を含む、適切なサイズの用量の栄養補助食品を調製する段階と、
適切なサイズの用量の薬物を前記栄養補助食品に混合する段階と、
ウマまたは他の動物に前記栄養補助食品を投与する段階と、を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/435,367 US7824706B2 (en) | 2003-05-09 | 2003-05-09 | Dietary supplement and method for the treatment of digestive tract ulcers in equines |
US10/435,367 | 2003-05-09 | ||
PCT/US2004/013555 WO2004100826A2 (en) | 2003-05-09 | 2004-05-03 | Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011279943A Division JP5583655B2 (ja) | 2003-05-09 | 2011-12-21 | 栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007501632A true JP2007501632A (ja) | 2007-02-01 |
JP5085131B2 JP5085131B2 (ja) | 2012-11-28 |
Family
ID=33416936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006532533A Expired - Lifetime JP5085131B2 (ja) | 2003-05-09 | 2004-05-03 | 栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法 |
JP2011279943A Expired - Lifetime JP5583655B2 (ja) | 2003-05-09 | 2011-12-21 | 栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011279943A Expired - Lifetime JP5583655B2 (ja) | 2003-05-09 | 2011-12-21 | 栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法 |
Country Status (19)
Country | Link |
---|---|
US (3) | US7824706B2 (ja) |
EP (1) | EP1626706B1 (ja) |
JP (2) | JP5085131B2 (ja) |
CN (1) | CN1794976B (ja) |
AR (1) | AR044271A1 (ja) |
AU (1) | AU2004238232B2 (ja) |
BR (1) | BRPI0410131B1 (ja) |
CA (1) | CA2522765C (ja) |
CO (1) | CO5690535A2 (ja) |
DK (1) | DK1626706T3 (ja) |
EG (1) | EG25067A (ja) |
JO (1) | JO3001B1 (ja) |
MX (1) | MXPA05012050A (ja) |
NZ (1) | NZ543965A (ja) |
PE (1) | PE20050105A1 (ja) |
PL (1) | PL1626706T3 (ja) |
SG (1) | SG172480A1 (ja) |
UY (1) | UY28311A1 (ja) |
WO (1) | WO2004100826A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010162040A (ja) * | 2004-03-17 | 2010-07-29 | Freedom Health Llc | 栄養補助食品及び消化器系関連障害の治療方法 |
JP2013146281A (ja) * | 2004-03-17 | 2013-08-01 | Freedom Health Llc | 栄養補助食品 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008002487A (es) * | 2005-08-25 | 2008-04-03 | Adm Alliance Nutrition Inc | Uso de dextrina en alimento para animales. |
WO2011139574A2 (en) | 2010-05-05 | 2011-11-10 | Applied Materials, Inc. | Hydrothermal synthesis of active materials and in situ spraying deposition for lithium ion battery |
AU2013204801B2 (en) * | 2012-05-23 | 2014-11-06 | Omniblend Innovation Pty Ltd | Composition and method for management of diabetes or pre-diabetes |
US10076549B2 (en) | 2012-11-28 | 2018-09-18 | Smartpak Equine Llc | Gastric health supplement and methods thereof |
JP2016506406A (ja) * | 2012-12-20 | 2016-03-03 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | ヒト以外の動物における毛の状態を改善するための方法 |
US20150132404A1 (en) * | 2013-11-08 | 2015-05-14 | George Aaron Custer | Equine feed for the reduction of ulcers in performance horses |
CN103750010B (zh) * | 2013-12-20 | 2015-06-24 | 余姚德诚科技咨询有限公司 | 一种防治马猝死症的饲料的制备方法 |
US11439676B2 (en) | 2018-10-16 | 2022-09-13 | Kaeco Group, Inc. | Method for prevention or treating gastrointestinal distress in humans using mastic gum compositions |
US10548917B2 (en) | 2016-05-23 | 2020-02-04 | Kaeco Group Inc. | Supplement for the prevention and treatment of gastrointestinal distress in horses and other species |
US9694042B1 (en) * | 2016-05-23 | 2017-07-04 | Kaeco Group, Inc. | Mastic gum top dressing for the prevention of gastrointestinal distress in horses and other species |
US20200113858A1 (en) * | 2018-10-15 | 2020-04-16 | Freedom Health, Llc | Human dietary supplement and method for treating digestive system and immune-related disorders |
CN109497556B (zh) * | 2018-11-27 | 2022-05-31 | 浙江华康药业股份有限公司 | 具有保护肠道屏障功能的低糖大豆燕麦粉及其制备方法 |
CN109463352B (zh) * | 2018-11-29 | 2020-08-07 | 深圳农畉农产品有限公司 | 一种降低生猪体内粪臭素的方法 |
US11307752B2 (en) | 2019-05-06 | 2022-04-19 | Apple Inc. | User configurable task triggers |
CA3143318C (en) * | 2019-06-14 | 2024-06-18 | Cj Cheiljedang Corporation | Composition for preventing, treating, or improving gastrointestinal diseases comprising strain of genus corynebacterium and culture thereof |
WO2021045045A1 (ja) * | 2019-09-02 | 2021-03-11 | 富士フイルム株式会社 | 家畜用飼料又は家畜用サプリメント、家畜の消化器系疾患治療中又は消化器系疾患治療後の体調回復促進剤、並びに家畜の消化器系疾患治療中又は消化器系疾患治療後の体調回復を促進する方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS619255A (ja) * | 1984-06-22 | 1986-01-16 | Kyodo Shiryo Kk | 単胃家畜の飼育方法 |
JPH06209719A (ja) * | 1993-01-13 | 1994-08-02 | Kyowa Hakko Kogyo Co Ltd | 飼 料 |
WO2002024002A2 (en) * | 2000-09-22 | 2002-03-28 | Mars Uk Limited | Food supplement |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS505568A (ja) | 1973-05-16 | 1975-01-21 | ||
GB1526553A (en) * | 1975-02-06 | 1978-09-27 | Du Pont Canada | Extraction of oil from oats |
US4038416A (en) * | 1975-09-11 | 1977-07-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition and method of the use thereof |
US4752618A (en) | 1984-07-12 | 1988-06-21 | New England Deaconess Hospital | Method of minimizing efects of infection through diet |
US4729898A (en) * | 1985-01-31 | 1988-03-08 | Joseph Brule | Hashed white meat based food product |
US4729896A (en) * | 1986-06-23 | 1988-03-08 | Pacific Kenyon Corp. | Buffered animal feed supplement block |
US4950656A (en) | 1987-02-17 | 1990-08-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
US5312636A (en) * | 1987-08-12 | 1994-05-17 | Valtion Teknillinen Tutkimuskeskus | Process for fractioning crop into industrial raw material |
US4847095A (en) * | 1987-09-11 | 1989-07-11 | Wendland's Farm Products, Inc. | Method for free choice horse feeding |
US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
US6020324A (en) | 1989-10-20 | 2000-02-01 | The Collaborative Group, Ltd. | Glucan dietary additives |
US5320846A (en) | 1991-04-17 | 1994-06-14 | New England Deaconess Hospital Corp. | Method and composition for testing patients with metabolic depleting diseases |
US5589186A (en) | 1993-01-29 | 1996-12-31 | Takeda Chemical Industries, Ltd. | Feed composition for ruminant animals and method of feeding ruminant animals with the same |
DE69418378T2 (de) * | 1993-02-09 | 1999-12-16 | Quaker Oats Co | Verfahren zur Herstellung einer transparenten, stabilen wässrigen Lösung von Haferproteinen, mit niedrigem Fettgehalt, und Produkt daraus |
US5605968A (en) * | 1993-03-17 | 1997-02-25 | Bridgestone Sports, Co., Ltd. | Golf ball |
US5759537A (en) | 1993-04-07 | 1998-06-02 | Lovesgrove Research Limited | Animal feeds |
US5505968A (en) * | 1993-07-02 | 1996-04-09 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture | Antemortem nutrient supplement for livestock |
PL178394B1 (pl) | 1994-02-04 | 2000-04-28 | Scotia Lipidteknik Ab | Lipofilowy preparat nośnikowy i środek farmaceutyczny zawierający lipofilowy preparat nośnikowy |
GB9418420D0 (en) * | 1994-09-13 | 1994-11-02 | Mckeown Neil A | Composition for the treatment of an energy imbalance in ruminents |
SE504664C2 (sv) | 1995-09-22 | 1997-03-24 | Scotia Lipidteknik Ab | Sätt att framställa fraktionerad olja, oljan, dess användning samt emulsionskomposition innehållande oljan |
US6200624B1 (en) | 1996-01-26 | 2001-03-13 | Abbott Laboratories | Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids |
JPH09262061A (ja) | 1996-03-28 | 1997-10-07 | Tanabe Seiyaku Co Ltd | ストレス緩和用飼料 |
CA2208827C (en) | 1996-07-09 | 2006-01-03 | Ben A. Steensma | Animal feed |
AU731297B2 (en) | 1997-03-13 | 2001-03-29 | Abbott Laboratories | Nutritional formula containing hydrolyzed protein and a fiber blend |
ATE275834T1 (de) | 1997-03-20 | 2004-10-15 | Coventry Group Ltd | Nährungsergänzungsmittel für kardiovasküläre gesundheit |
US5922766A (en) | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
US5976579A (en) * | 1997-07-03 | 1999-11-02 | Mclean; Linsey | Nutritional supplement for the prevention and treatment of excessive intestinal permeability |
SE511025C2 (sv) | 1997-10-03 | 1999-07-26 | Probi Ab | Foderprodukt för häst omfattande Lactobacillus plantarum JI:1 samt Lactobacillus plantarum JI:1 och användning därav |
US5972985A (en) | 1997-11-03 | 1999-10-26 | Cytos Pharmaceuticals, Llc | Histidine containing nutriceutical compositions |
JP3554219B2 (ja) * | 1998-03-31 | 2004-08-18 | キヤノン株式会社 | 排気装置と排気方法、および堆積膜形成装置と堆積膜形成方法 |
WO1999053772A1 (en) | 1998-04-17 | 1999-10-28 | Alltech, Inc. | Compositions for removal of mycotoxins from feed |
EP0954139B1 (en) * | 1998-05-01 | 2005-04-06 | Hewlett-Packard Company, A Delaware Corporation | Methods of altering dynamic decision trees |
US20020054917A1 (en) * | 1998-08-14 | 2002-05-09 | Gohlke Marcus B. | Compositions comprising beta glucan and lactoferrin, and methods for their use |
AU773696B2 (en) * | 1998-10-06 | 2004-06-03 | Mars, Incorporated | Animal stereotypy |
US6156355A (en) | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
CA2336462C (en) | 1999-05-03 | 2008-04-29 | Alltech, Inc. | Novel compositions and methods for reduction of effects of endophyte-infected forages |
US6117458A (en) | 1999-06-01 | 2000-09-12 | Morgan; Norma B. | Swine feed composition |
IL148142A (en) | 1999-09-09 | 2005-06-19 | Nestle Sa | Method for improving condition of elderly pets and pet food therefor |
US6410067B1 (en) * | 2000-01-27 | 2002-06-25 | Morton Jay Kanter | Equine neutraceuticals |
GB0008249D0 (en) | 2000-04-04 | 2000-05-24 | Mars Uk Ltd | Supplementation of engine feedstuffs |
US6451370B1 (en) | 2000-05-25 | 2002-09-17 | Tom Anderson | Complete animal feed with potato component |
US20020044988A1 (en) * | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
AU2002233639B2 (en) | 2001-02-15 | 2007-03-01 | Adeka Corporation | Products containing $G(b)-glucan |
AU2002254007B2 (en) | 2001-02-22 | 2006-09-21 | Purdue Research Foundation | Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer |
US6835558B2 (en) * | 2002-02-04 | 2004-12-28 | General Mills, Inc. | Beta-glucan compositions and process therefore |
JP4307800B2 (ja) | 2002-07-23 | 2009-08-05 | 味の素ゼネラルフーヅ株式会社 | マンノオリゴ糖を含有する免疫賦活組成物 |
FI20031004A0 (fi) | 2003-07-03 | 2003-07-03 | Raisio Benecol Oy | Uusi syötävä koostumus |
-
2003
- 2003-05-09 US US10/435,367 patent/US7824706B2/en not_active Expired - Lifetime
-
2004
- 2004-05-03 AU AU2004238232A patent/AU2004238232B2/en not_active Expired
- 2004-05-03 SG SG2007084932A patent/SG172480A1/en unknown
- 2004-05-03 DK DK04751112T patent/DK1626706T3/en active
- 2004-05-03 CA CA2522765A patent/CA2522765C/en not_active Expired - Lifetime
- 2004-05-03 CN CN200480012335XA patent/CN1794976B/zh not_active Expired - Lifetime
- 2004-05-03 EP EP04751112.6A patent/EP1626706B1/en not_active Expired - Lifetime
- 2004-05-03 NZ NZ543965A patent/NZ543965A/en unknown
- 2004-05-03 PL PL04751112T patent/PL1626706T3/pl unknown
- 2004-05-03 JP JP2006532533A patent/JP5085131B2/ja not_active Expired - Lifetime
- 2004-05-03 MX MXPA05012050A patent/MXPA05012050A/es active IP Right Grant
- 2004-05-03 BR BRPI0410131-6A patent/BRPI0410131B1/pt active IP Right Grant
- 2004-05-03 WO PCT/US2004/013555 patent/WO2004100826A2/en active Application Filing
- 2004-05-06 JO JOP/2004/0053A patent/JO3001B1/ar active
- 2004-05-06 UY UY28311A patent/UY28311A1/es not_active Application Discontinuation
- 2004-05-06 PE PE2004000460A patent/PE20050105A1/es not_active Application Discontinuation
- 2004-05-07 AR ARP040101569A patent/AR044271A1/es not_active Application Discontinuation
-
2005
- 2005-09-13 US US11/225,562 patent/US7993669B2/en active Active
- 2005-11-07 EG EGNA2005000702 patent/EG25067A/xx active
- 2005-11-08 CO CO05113515A patent/CO5690535A2/es not_active Application Discontinuation
-
2010
- 2010-11-01 US US12/917,237 patent/US20110045107A1/en not_active Abandoned
-
2011
- 2011-12-21 JP JP2011279943A patent/JP5583655B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS619255A (ja) * | 1984-06-22 | 1986-01-16 | Kyodo Shiryo Kk | 単胃家畜の飼育方法 |
JPH06209719A (ja) * | 1993-01-13 | 1994-08-02 | Kyowa Hakko Kogyo Co Ltd | 飼 料 |
WO2002024002A2 (en) * | 2000-09-22 | 2002-03-28 | Mars Uk Limited | Food supplement |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010162040A (ja) * | 2004-03-17 | 2010-07-29 | Freedom Health Llc | 栄養補助食品及び消化器系関連障害の治療方法 |
JP2013146281A (ja) * | 2004-03-17 | 2013-08-01 | Freedom Health Llc | 栄養補助食品 |
Also Published As
Publication number | Publication date |
---|---|
CN1794976B (zh) | 2010-05-26 |
BRPI0410131B1 (pt) | 2015-08-04 |
EP1626706A2 (en) | 2006-02-22 |
JP2012100672A (ja) | 2012-05-31 |
CA2522765A1 (en) | 2004-11-25 |
US7993669B2 (en) | 2011-08-09 |
US20060008509A1 (en) | 2006-01-12 |
AR044271A1 (es) | 2005-09-07 |
PL1626706T3 (pl) | 2015-08-31 |
PE20050105A1 (es) | 2005-02-20 |
EP1626706A4 (en) | 2008-07-23 |
AU2004238232A1 (en) | 2004-11-25 |
UY28311A1 (es) | 2004-06-30 |
AU2004238232B2 (en) | 2010-04-22 |
SG172480A1 (en) | 2011-07-28 |
CO5690535A2 (es) | 2006-10-31 |
US7824706B2 (en) | 2010-11-02 |
JP5583655B2 (ja) | 2014-09-03 |
WO2004100826A3 (en) | 2005-03-10 |
EG25067A (en) | 2011-07-26 |
EP1626706B1 (en) | 2015-01-28 |
DK1626706T3 (en) | 2015-04-20 |
BRPI0410131A (pt) | 2006-05-16 |
MXPA05012050A (es) | 2006-06-23 |
JP5085131B2 (ja) | 2012-11-28 |
WO2004100826A2 (en) | 2004-11-25 |
JO3001B1 (ar) | 2016-09-05 |
CA2522765C (en) | 2015-02-03 |
CN1794976A (zh) | 2006-06-28 |
US20040224036A1 (en) | 2004-11-11 |
US20110045107A1 (en) | 2011-02-24 |
NZ543965A (en) | 2010-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5583655B2 (ja) | 栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法 | |
Jouany et al. | Effect of live yeast culture supplementation on apparent digestibility and rate of passage in horses fed a high-fiber or high-starch diet | |
Andrews et al. | Nutritional management of gastric ulceration | |
US20090246314A1 (en) | Equine whole food supplements | |
Greene et al. | A review of Asian and African elephant gastrointestinal anatomy, physiology, and pharmacology: Elephant gastrointestinal anatomy, physiology, and pharmacology | |
US7988989B2 (en) | Nutritional product for enhancing growth and/or strengthening the immune system of equine foals | |
Ralston | Evidence-based equine nutrition | |
US8197842B2 (en) | Dietary supplement and method | |
EP3065558B1 (en) | Feedstuff for equids | |
Jarvis | Nutrition of the aged horse | |
RU2368251C2 (ru) | Пищевая и кормовая добавки и их применение | |
Pugh | Feeding the geriatric horse | |
Moore | Rabbit Nutrition and Nutritional Healing | |
JP3831157B2 (ja) | 便臭改善剤 | |
CN115886145A (zh) | 一种猫用化毛球片及其制备方法 | |
Club et al. | Your One Source for the Horse | |
JP2005080542A (ja) | 馬用健康機能食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070502 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100304 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110914 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120814 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120905 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5085131 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150914 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |